نتایج جستجو برای: polysaccharide vaccine

تعداد نتایج: 127703  

Journal: :The European respiratory journal 2005
D A van Kessel H van Velzen-Blad J M M van den Bosch G T Rijkers

As a defective anti-polysaccharide response can exist in the absence of an immunoglobulin deficiency, a series of 26 patients with bronchiectasis of unknown aetiology was vaccinated with a 23-valent pneumococcal polysaccharide vaccine. All patients suffered from recurrent respiratory tract infections. When measuring total antibody levels to pneumococcal serotypes 3, 4 and 9, a normal polysaccha...

Journal: :The New England journal of medicine 2015
Marc J M Bonten Susanne M Huijts Marieke Bolkenbaas Chris Webber Scott Patterson Samantha Gault Cornelis H van Werkhoven Anna M M van Deursen Elisabeth A M Sanders Theo J M Verheij Michael Patton Anne McDonough Anita Moradoghli-Haftvani Helen Smith Tracey Mellelieu Michael W Pride Graham Crowther Beate Schmoele-Thoma Daniel A Scott Kathrin U Jansen Rita Lobatto Bas Oosterman Nils Visser Esther Caspers Andre Smorenburg Emilio A Emini William C Gruber Diederick E Grobbee

BACKGROUND Pneumococcal polysaccharide conjugate vaccines prevent pneumococcal disease in infants, but their efficacy against pneumococcal community-acquired pneumonia in adults 65 years of age or older is unknown. METHODS In a randomized, double-blind, placebo-controlled trial involving 84,496 adults 65 years of age or older, we evaluated the efficacy of 13-valent polysaccharide conjugate va...

Journal: :Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008
Lisa A Jackson Edward N Janoff

Pneumococcal polysaccharide vaccine has been licensed for use in the United States for >30 years, and two-thirds of the elderly population in the United States have received this vaccine. Observational studies have demonstrated that pneumococcal polysaccharide vaccine reduces the risk of invasive pneumococcal disease in immunocompetent elderly individuals, but neither observational studies nor ...

Journal: :Journal of occupational and environmental medicine 2016
Nomana M Khan Emily S Jentes Clive Brown Pauline Han Sowmya R Rao Phyllis Kozarsky Stefan H F Hagmann Regina C LaRocque Edward T Ryan

OBJECTIVES The aim of the study was to understand more about pre-travel preparations and itineraries of business and occupational travelers. METHODS De-identified data from 18 Global TravEpiNet clinics from January 2009 to December 2012 were analyzed. RESULTS Of 23,534 travelers, 61% were non-occupational and 39% occupational. Business travelers were more likely to be men, had short times t...

Journal: :JAMA 1999
L A Jackson P Benson V P Sneller J C Butler R S Thompson R T Chen L S Lewis G Carlone F DeStefano P Holder T Lezhava W W Williams

CONTEXT Revaccination of healthy adults with pneumococcal polysaccharide vaccine (PPV) within several years of first vaccination has been associated with a higher than expected frequency and severity of local injection site reactions. The risk of adverse events associated with revaccination of elderly and chronically ill persons 5 or more years after first vaccination, as is currently recommend...

2008

OBJECTIVES: To describe the characteristics of pneumococcal isolates obtained from patients with invasive pneumococcal disease in The Gambia. METHODS: Pneumococcal isolates were obtained from children aged < or =6 years with invasive pneumococcal disease during a Haemophilus influenzae vaccine effectiveness study (1997-2002) and from patients with invasive pneumococcal disease admitted to the M...

2008
Javier M Santander Kenneth L. Roland Roy Curtiss

The synthesis of Vi polysaccharide, a major virulence determinant in Salmonella enterica serotype Typhi (S. Typhi), is under the control of two regulatory systems, ompR-envZ and rscB-rscC, which respond to changes in osmolarity. Some S. Typhi isolates exhibit over-expression of Vi polysaccharide, which masks clinical detection of LPS O-antigen. This variation in Vi polysaccharide and O-antigen ...

Journal: :The Journal of allergy and clinical immunology 2010
Anne Balloch Paul V Licciardi Fiona M Russell Edward K Mulholland Mimi L K Tang

1 0.17 (0.13-0.22) 2.04 (1.49-2.80) <.0001 2 0.28 (0.23-0.35) 12.48 (9.66-16.12) <.0001 3 0.37 (0.26-0.53) 13.74 (10.55-17.91) <.0001 4 0.08 (0.06-0.10) 2.37 (1.76-3.20) <.0001 5 0.26 (0.20-0.34) 2.77 (2.15-3.57) <.0001 6B 0.14 (0.12-0.17) 0.31 (0.23-0.42) <.05 7F 0.10 (0.08-0.14) 2.58 (1.98-3.37) <.0001 8 0.26 (0.20-0.32) 13.59 (10.72-17.23) <.0001 9N 0.12 (0.09-0.15) 3.06 (2.18-4.30) <.0001 9...

Journal: :JAMA 2005
Catherine A Lexau Ruth Lynfield Richard Danila Tamara Pilishvili Richard Facklam Monica M Farley Lee H Harrison William Schaffner Arthur Reingold Nancy M Bennett James Hadler Paul R Cieslak Cynthia G Whitney

CONTEXT A conjugate vaccine targeting 7 pneumococcal serotypes was licensed for young children in 2000. In contrast to the 23-valent polysaccharide vaccine used in adults, the 7-valent conjugate vaccine affects pneumococcal carriage and transmission. Early after its introduction, incidence of invasive pneumococcal disease declined among older adults, a group at high risk for pneumococcal diseas...

2014
Juan José Picazo Fernando González - Romo Amós García Rojas Emilio Peréz - Trallero Pedro Gil Gregorio Rafael de la Cámara María Luisa Morató Alejandro Rodríguez José Barberán Vicente Domínguez Hernández Linares Rufo Isabel Jimeno Sanz José María Portolés Francisco Sanz Herrero Valle García - Sánchez

4. Polysaccharide vaccine (PPV23), used in subjects older than 2 years since decades ago, includes a greater number of serotypes (23), but it does not generate immune memory, antibody levels decrease with time, causes an immune tolerance phenomenon, have no effect on nasopharyngeal colonization and has not shown vaccine effectiveness in these risk groups in the United Kingdom despite a 75% of v...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید